Albain et al listed prognostic features for patients with extensive non-small cell lung carcinoma (ENSCLC). These can help identify patients who may have different short-term survivals. The authors are from the Southwest Oncology Group (SWOG).
Patient selection:
(1) non-small cell lung cancer (squamous cell, adenocarcinoma, large cell undifferentiated)
(2) "extensive" (all the patients had metastases, which infers Stage IV)
Parameters:
(1) SWOG/ECOG performance status (PS)
(2) hemoglobin in g/dL
(3) age in years
(4) serum LDH
|
SWOG PS |
Hemoglobin |
Age in Years |
LDH |
Group |
|
0 or 1 |
>= 11.0 |
>= 47 |
NA |
I |
|
0 or 1 |
< 11.0 |
>= 47 |
NA |
II |
|
0 or 1 |
>= 11.0 |
< 47 |
NA |
II |
|
0 or 1 |
< 11.0 |
< 47 |
NA |
II |
|
2, 3 or 4 |
NA |
NA |
normal |
II |
|
2, 3 or 4 |
NA |
NA |
increased |
III |
|
Group |
Probability of 1 Year Survival |
Probability of 2 Year Survival |
|
I |
27% |
8% |
|
II |
16% |
3% |
|
III |
6% |
1% |
Favorable variables in Cox multivariate analysis (Table 5, page 1621):
(1) performance scale 0 or 1
(2) treated with cisplatin
(3) female gender
(4) age >= 70 years
(5) hemoglobin >= 11.0 g/dL
(6) normal serum LDH
(7) normal serum calcium
(8) single metastasis
Specialty: Hematology Oncology, Surgery, general, Pulmonology
ICD-10: ,
